Literature DB >> 12855259

Design of a prognostic index score for metastatic nasopharyngeal carcinoma.

Y K Ong1, D M Heng, B Chung, S S Leong, J Wee, K W Fong, T Tan, E H Tan.   

Abstract

The survival outcome of patients with systemic cancer differs significantly between individuals even within the same tumour type. We set out to illustrate this by analysing the factors determining survival in patients with metastatic disease from nasopharyngeal carcinoma (NPC) and to design a scoring system based on these prognostic factors. Patients referred between January 1994 and December 1999 were retrospectively analysed. Factors analysed included patient (age group, gender, performance status (BS) at diagnosis of metastases), disease (number of metastatic sites, specific metastatic sites, disease-free interval (DFI), metastases at presentation, presence of locoregional recurrence), and laboratory factors (leucocyte count, haemoglobin level, albumin level). Univariate and multivariable analyses were performed using the Cox proportion hazards model. A numerical score was derived from the regression coefficients of each independent prognostic variable. The prognostic index score (PIS) of each patient was calculated by totalling up the scores of each independent variable. Independently significant, negative prognostic factors were liver metastasis, lung metastasis, anaemia, poor PS, distant metastasis at initial diagnosis, and a DFI of <6 months. Three prognostic groups based on the PIS were obtained: (i) good risk (PIS=0-6); (ii) intermediate risk (7-10); (iii) poor risk (>or=11). The median survivals for these groups were 19.5, 10, and 5.8, months, respectively, (log rank test: P<0.0001). The variable prognosis of patients with disseminated NPC can be assessed by using easily available clinical information (patient, disease and laboratory factors). The PIS system will need to be validated on prospectively collected data of another cohort of patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855259     DOI: 10.1016/s0959-8049(03)00310-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  37 in total

1.  Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis.

Authors:  Shao-xuan Hu; Xiao-hui He; Mei Dong; Bo Jia; Sheng-yu Zhou; Jian-liang Yang; Sheng Yang; Chang-Gong Zhang; Peng Liu; Yan Qin; Lin Gui
Journal:  Med Oncol       Date:  2015-07-29       Impact factor: 3.064

2.  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.

Authors:  Lujun Shen; Jun Dong; Sheng Li; Yue Wang; Annan Dong; Wanhong Shu; Ming Wu; Changchuan Pan; Yunfei Xia; Peihong Wu
Journal:  Oncologist       Date:  2015-02-06

3.  Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis.

Authors:  Dirk M Pegtel; Aravind Subramanian; Tzung-Shiahn Sheen; Ching-Hwa Tsai; Todd R Golub; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Changes in c-Kit expression levels during the course of radiation therapy for nasopharyngeal carcinoma.

Authors:  Feng Jiang; Wei Hu; Bicheng Zhang; Jing Xu; Yongjie Shui; Xiaofeng Zhou; Xiaoqiu Ren; Xiaozhong Chen; Li Shen; Qichun Wei
Journal:  Biomed Rep       Date:  2016-09-12

5.  Prognostic stratification of patients with metastatic nasopharyngeal carcinoma using a clinical and biochemical scoring system.

Authors:  Jeremy Chee; Kwok Seng Loh; Ivan Tham; Francis Ho; Lea Choung Wong; Chee Seng Tan; Boon Cher Goh; Chwee Ming Lim
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

6.  Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.

Authors:  Ying Jin; Yan-Xia Shi; Xiu-Yu Cai; Xi-Ya Xia; Yu-Chen Cai; Ye Cao; Wei-Dong Zhang; Wei-Han Hu; Wen-Qi Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-10       Impact factor: 4.553

7.  Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival.

Authors:  Changchuan Pan; Ni He; Ming Zhao; Yangkui Gu; Zilin Huang; Wang Li; Yunfei Xia; Peihong Wu
Journal:  Med Oncol       Date:  2010-09-04       Impact factor: 3.064

8.  Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.

Authors:  Qing-Li Kong; Li-Juan Hu; Jing-Yan Cao; Yi-Jun Huang; Li-Hua Xu; Yi Liang; Dan Xiong; Su Guan; Bao-Hong Guo; Hai-Qiang Mai; Qiu-Yan Chen; Xing Zhang; Man-Zhi Li; Jian-Yong Shao; Chao-Nan Qian; Yun-Fei Xia; Li-Bing Song; Yi-Xin Zeng; Mu-Sheng Zeng
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

9.  Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.

Authors:  Daniel D Von Hoff; Drew W Rasco; Elisabeth I Heath; Pamela N Munster; Jan H M Schellens; Nicolas Isambert; Christophe Le Tourneau; Bert O'Neil; Ron H J Mathijssen; Jose A Lopez-Martin; W Jeff Edenfield; Miguel Martin; Patricia M LoRusso; Gordon L Bray; Jorge DiMartino; Aaron Nguyen; Kejian Liu; Eric Laille; Johanna C Bendell
Journal:  Clin Cancer Res       Date:  2018-05-15       Impact factor: 12.531

10.  RASAL2 inhibited the proliferation and metastasis capability of nasopharyngeal carcinoma.

Authors:  Zhongliang Wang; Jiang Wang; Yue Su; Zhen Zeng
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.